Author

A. Hock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:Bayesian inference· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

A. Hedley· 1 shared A. M. Afzal· 1 shared B. Kruspig· 1 shared B. Zhang· 1 shared C. Dick· 1 shared C. Martins· 1 shared C. Nixon· 1 shared D. Murphy· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Hedley

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Flexible fitting of PROTAC concentration-response curves with changepoint Gaussian Processes

E. Semenova, M. L. Guerriero, B. Zhang, A. Hock, P. Hopcroft, G. Kadamur, A. M. Afzal, S. E. Lazic

This paper introduces a Bayesian changepoint Gaussian Processes model to automatically fit PROTAC concentration-response curves, enabling accurate parameter estimation and compound ranking without manual intervention.

bioRxiv · Nov 13, 2020Cell Biology

The ERBB network facilitates KRAS-driven lung tumorigenesis

B. Kruspig, T. Monteverde, S. Neidler, A. Hock, E. Kerr, C. Nixon, W. Clark, A. Hedley, C. Dick, K. Vousden, C. Martins, D. Murphy

This study shows that the ERBB network is required for KRAS-driven lung tumorigenesis and that inhibiting it enhances MEK inhibitor efficacy in treating such cancers.

bioRxiv · Apr 9, 2018Cancer Biology